LOG IN
SIGN UP
MARKET
AZN
AZN
Astrazeneca Plc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
66.07
-0.95
-1.42%
Pre Market: 64.19 -1.88 -2.85% 07:45 07/01 EDT
OPEN
65.64
PREV CLOSE
67.02
HIGH
66.42
LOW
65.19
VOLUME
55.37K
TURNOVER
--
52 WEEK HIGH
71.70
52 WEEK LOW
53.63
MARKET CAP
204.75B
P/E (TTM)
-199.1260
1D
5D
1M
3M
1Y
5Y
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
Benzinga · 7h ago
AstraZeneca Meets Primary Endpoints in Late-Stage Liver, Biliary Tract Cancers Trials
MT Newswires · 7h ago
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine
Benzinga · 8h ago
AstraZeneca signs new three-year deal with Oxford Biomedica for COVID shot
U.K.-based biotech Oxford Biomedica (OTCPK:OXBDF) announced on Friday that the company entered into a...
Seekingalpha · 9h ago
Oxford Biomedica Signed New Three year Agreement with AstraZeneca
Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, today announces that it has signed a new three year Master Services & Development Agreement ("the Agreement") with AstraZeneca UK Ltd ("AstraZeneca...
Benzinga · 10h ago
Oxford BioMedica extends Covid vaccine deal with AstraZeneca
Oxford BioMedica has extended its partnership with AstraZeneca, agreeing a new three-year contract to manufacture Covid-19 vaccines if the UK drugmaker presses on with mass production of the jab. The specialist pharmaceutical manufacturer, which also make...
Financial Times · 11h ago
AstraZeneca Enters New 3-Year Agreement with Oxford Biomedica
MT Newswires · 11h ago
UPDATE 1-UK Stocks-Factors to watch on July 1
UPDATE 1-UK Stocks-Factors to watch on July 1
Reuters · 12h ago
No Data
Learn about the latest financial forecast of AZN. Analyze the recent business situations of Astrazeneca Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 6 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AZN stock price target is 71.80 with a high estimate of 80.00 and a low estimate of 59.00.
Current 65.77
EPS
Actual
Estimate
0.240.480.710.95
Institutional Holdings
Institutions: 1.22K
Institutional Holdings: 559.06M
% Owned: 18.04%
Shares Outstanding: 3.10B
TypeInstitutionsShares
Increased
332
41.13M
New
113
4.84M
Decreased
289
30.06M
Sold Out
81
2.63M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Pharmaceuticals
+0.43%
Pharmaceuticals & Medical Research
+0.67%
Key Executives
Non-Executive Chairman/Independent Director
Leif Johansson
Chief Executive Officer/Executive Director
Pascal Soriot
Chief Financial Officer/Executive Director
Aradhana Sarin
Corporate Executive
Marc Dunoyer
Chief Human Resource Officer/General Counsel
Jeffrey Pott
Executive Vice President/Chief Compliance Officer
Katarina Ageborg
Executive Vice President
Pam Cheng
Executive Vice President
Ruud Dobber
Executive Vice President
David Fredrickson
Executive Vice President
Susan Galbraith
Executive Vice President
Menelas Pangalos
Executive Vice President
Iskra Reic
Executive Vice President
Leon Wang
Secretary
Adrian Kemp
Non-Executive Director
Marcus Wallenberg
Non-Executive Independent Director
Euan Ashley
Non-Executive Independent Director
Philip Broadley
Non-Executive Independent Director
Michel Demare
Non-Executive Independent Director
Deborah Eldracher
Non-Executive Independent Director
Diana Layfield
Non-Executive Independent Director
Sherilyn Mccoy
Non-Executive Independent Director
Tony Mok
Non-Executive Independent Director
Nazneen Rahman
Non-Executive Independent Director
Andreas Rummelt
No Data
No Data
About AZN
AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Webull offers kinds of AstraZeneca plc (ADR) stock information, including NASDAQ:AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading AZN stock methods without spending real money on the virtual paper trading platform.